Todd Shegog - 23 Feb 2022 Form 4 Insider Report for Forma Therapeutics Holdings, Inc.

Role
SVP, Chief Financial Officer
Signature
/s/ Jeannette Potts, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
23 Feb 2022
Net transactions value
-$55,605
Form type
4
Filing time
25 Feb 2022, 16:04:13 UTC
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FMTX Common Stock Sale $55,605 -5,687 -20% $9.78 22,813 23 Feb 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.61 to $10.005. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Remarks:

In a Form 4 filed by the reporting person on March 2, 2021, the box indicating "no longer subject to Section 16" was inadvertently checked. The reporting person has remained subject to Section 16, and all changes in beneficial ownership subsequent to such Form 4 have been properly reported on a timely basis.